勤浩医药递表港交所 华泰国际为保荐人

Company Overview - Company has submitted a listing application to the Hong Kong Stock Exchange, sponsored by Huatai International [1] - Focuses on developing potential best-in-class targeted therapies in oncology, with core technology centered around the RAS signaling pathway and synthetic lethality mechanisms [1] Product Pipeline - As of the last feasible date, the company has seven self-developed drug candidates, including four in clinical stages, one approved by the National Medical Products Administration (NMPA) and the FDA for IND, and two in preclinical stages [1] - Core product GH21 is a potential best-in-class allosteric SHP2 inhibitor currently in Phase 2 clinical trials, with IND approval for monotherapy in advanced solid tumors obtained in November 2021 [1] - GH21's combination therapies with Gossamer and Osimertinib received IND approvals in June 2024 and November 2023, respectively, and are undergoing Phase 1b/2 and Phase 2 clinical trials in China [1] Additional Drug Candidates - The RAS signaling pathway pipeline includes GH55, a potential best-in-class dual mechanism ERK1/2 inhibitor for treating MAPK pathway-activated solid tumors, currently in Phase 1 clinical trials in China [2] - The synthetic lethality pipeline includes GH56 (MTA synergistic PRMT5 inhibitor), GH2616 (KIF18A inhibitor), and GH31 (MAT2A inhibitor), all of which have received IND approvals and are in various stages of clinical trials in China [2] Market Potential - The global oncology drug market is projected to grow from $262.1 billion in 2024 to $646.1 billion by 2033, while the Chinese market is expected to increase from $37.2 billion to $123.8 billion [2] - Sub-segments such as SHP2 inhibitors and synthetic lethality drugs are anticipated to experience rapid growth in the future [2]